ArticleInternational journal of clinical and experimental pathology2018
Immunohistochemical assessment of autophagic protein LC3B and p62 levels in glioma patients.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Reprogramming Autophagy to Strengthen Antitumour Immunity: Advances in Immunotherapeutic Strategies.Immunology · 2026Review
- Dual biomarker role of PD-L1 and LC3B in glioblastoma: prognostic and therapeutic potential.Neurosurgical review · 2026Review
- Review
- Investigating the Association between the Autophagy Markers LC3B,International journal of molecular sciences · 2024Article
- Immunohistochemical Profile of p62/SQSTM1/Sequestosome-1 in Human Low- and High-Grade Intracranial Meningiomas.Analytical cellular pathology (Amsterdam) · 2024Article
- Review
- Immunoexpression of p62/SQSTM1/Sequestosome-1 in human primary and recurrent IDH1/2 wild-type glioblastoma: A pilot study.Oncology letters · 2022Article
- Improper Proteostasis: Can It Serve as Biomarkers for Neurodegenerative Diseases?Molecular neurobiology · 2022Review
- The Pathological Evaluation of Autophagy-Related Protein (LC3B) and Its Association with the Infiltration of Immune Cells in Glioma.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma is a serious malignant central nervous system disease. Autophagy is a basic cellular catabolic mechanism maintaining the cellular homeostasis through degradation of unnecessary molecules and components and reusing them. Autophagy also promotes development, progression and anticancer therapy resistance of many types of human cancers. In this study, we detected the expression of two autophagic protein LC3B and p62 in 81 glioma tissues by immunohistochemistry analysis. LC3B and p62 was highly expressed in high-grade glioma tissues, compared with low-grade glioma tissues. High levels of LC3B and p62 protein were also associated with advanced tumor stages, worse relapse-free survival (RFS) and overall survival (OS) in glioma patients, but not with patients' age, gender or KPS. Additionally, there was a statistically positive correlation between the expression of LC3B and p62 in glioma tissues. Therefore, we determined LC3B and p62 which contributed to autophagy behavior promoted development and poor prognosis of malignant gliomas. Therapeutic methods based on autophagy or targeting LC3B or p62 may be considered as a potential therapeutic strategy to retard progression of malignant gliomas.
Indexed as
Identifiers
31938176PMC6958015W3028449922What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.